Ed Kaye, Sarepta Therapeutics interim CEO, speaks to CNBC's Meg Tirrell about what's next for the company following FDA's recent approval of muscular dystrophy drug eteplirsen.
CNBC's Meg Tirrell reports the latest of Gilead, including the company's $5 billion debt offering and Jefferies analysts saying a deal may be imminent.
Kevin Sharer, Harvard Business School, discusses competition in the pharmaceutical industry and balancing drug prices and profits.
ASTERIAS BIOTHERAPEUTICS SAYS STEM CELL THERAPY AST-OPC1 MEETS GOAL OF SMALL STUDY OF PATIENTS PARALYZED BY SPINAL CORD INJURY- INTERIM DATA.
NEW YORK, Sept 14- An experimental stem cell therapy developed by Asterias Biotherapeutics restored some movement to patients paralyzed by recent spinal cord injuries, according to interim data from a small study being presented on Wednesday. One of the five patients in the trial regained use of both arms and hands, and is now able to feed himself, send texts on a...
Guggenheim Securities managing director Eric Wasserstrom weighs in on the big changes and next steps for Wells Fargo.
CNBC's Meg Tirrell takes a look at what may be ahead on the horizon for healthcare, with the likes of Obamacare and drug prices in the midst of the presidential campaign.
"Fast Money Halftime Report" trader Jon Najarian discusses unusual activity in biotech stock Novavax.
"Fast Money" trader Dan Nathan discusses why the S&P Biotech ETF (XBI) caught his eye.
Max Blankfeld, COO of FamilyTreeDNA.com, discusses the genetic testing industry, pricing and procedure.
The health care and technology conglomerate agreed to acquire Cepheid for $35 per share in cash.
Chris Raymond, Raymond James managing director and senior biotech analyst, shares his bullish take on Abbvie. The "Fast Money Halftime Report" traders and Barbara Doran, Yorkbridge director and senior portfolio manager, weigh in.
An inspection by the FDA uncovered problems with how the blood-testing startup collected patient data.
CNBC's Meg Tirrell reports that a House committee has sent a letter to Mylan for information on the EpiPen price increase.
CNBC's Meg Tirrell reports on Mylan's decision to launch a generic EpiPen as a way of cutting the cost of the treatment.
Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
Brad Arthur, Black Rock Pharmacy co-owner, shares his take on the rising drug prices and the pharma supply chain.
Ross Muken, Evercore ISI managing director, discusses the pharmaceutical supply chain and profits.
Who gets how much of your healthcare dollar? CNBC's Meg Tirrell explains the drug pipeline.
Ralph Nader, former presidential candidate and consumer advocate, responds to Mylan and what she had to say about the EpiPen pricing outrage.